Dry eye (DE) is recently recognized as a multifactorial disease where loss of homeostasis of the tear film is the central pathophysiological characteristic.\[[@ref1]\] DE diseases are often classified as aqueous deficient or evaporative DE. Tear-deficient DE can be mainly categorized as Sjogren\'s syndrome DE (SSDE) and non-SSDE (NSSDE). Artificial tears are often used in the treatment of DE. Moreover, inflammation in the pathogenesis of DE received more and more attention.\[[@ref2][@ref3][@ref4][@ref5]\] Therefore, anti-inflammatory drugs such as topical corticosteroids, tetracyclines, and topical cyclosporine A are prescribed.\[[@ref6][@ref7]\]

Interleukin-33 (IL-33), as a novel member of the IL-1 cytokine family, is broadly expressed by different tissues, such as smooth muscle cells, epithelial cells, fibroblasts, keratinocytes, dendritic cells, and activated macrophages.\[[@ref8][@ref9]\] The orphan IL-1 receptor, ST2, serves as the binding subunit for IL-33. The ST2 is expressed on mast cells, Th2 cells, and eosinophils and is necessary for induction of Th2 responses.\[[@ref10]\] IL-33 has been implicated in asthma, allergic conjunctivitis, and anaphylactic responses.\[[@ref11][@ref12][@ref13]\]

Th2 responses have recently been reported to play a role in Sjogren syndrome (SS), and Th2-associated cytokines were also detected in the tears of human DE subjects.\[[@ref14][@ref15]\] Besides, Th1 and Th17 responses were also involved in DE, whereas the role of Treg in DE was not clear.\[[@ref15]\] Therefore, the aim of this study was to evaluate whether the IL-33 is involved in the pathogenesis in DE and its correlation with Th cytokines.

Methods {#sec1-2}
=======

Study subjects {#sec2-1}
--------------

Sixty DE patients were recruited between 2016 and 2017 from our hospital. Primary SSDE and NSSDE were diagnosed clinically according to the criteria set by the International DE workshop report.\[[@ref16]\] All enrolled patients presented with symptoms (dryness, sandy/gritty feeling, burning/stinging, sense of eye pressure, pain, sensitivity to light, and eye congestion) for at least 6 months and used only artificial tears that did not contain preservatives. All patients underwent tear film breakup time (TBUT), Schirmer I test, and corneal fluorescein staining in sequence. Each eye was examined separately at sufficient time intervals (more than 10 min). Besides, the interval between usage of artificial tears and any measurement was at least 2 h. Due to the unique female-to-male prevalence ratio in SS patients (Female: Male 9:1), we included only female patients in this study.

Exclusion criteria included the history of ocular surgery, contact lens use, and other ocular surface inflammation or infection. Patients who had morphologic changes in meibomian glands, such as vascular dilation, acinar atrophy, or orifice metaplasia, on the posterior lid margin were also excluded from our study. Patients on immune modulators and steroids at present or within 1 month were excluded. Thirty normal participants with comparable age and sex were those without ocular diseases or other basic diseases. This study was approved by the local Ethical Committee (No. 2015101001) and informed consent was obtained from each participant.

All the following examinations were done on each eye separately at sufficient time intervals (more than 10 min) to minimize the impact of having the same researcher conduct the experiments.

Symptom scores {#sec2-2}
--------------

Eight most frequent symptoms (eyestrain, dryness, sandy/gritty feeling, burning/stinging, sense of eye pressure, pain, sensitivity to light, and eye congestion) of DE were evaluated. Each symptom was scored from 0 to 9 with a maximum total score of 72.

Tear film breakup time test {#sec2-3}
---------------------------

Fluorescein strips wetted with 0.9% sodium chloride were gently applied to the inferior palpebral conjunctiva. After instillation of fluorescein and 3 or 4 times of blinking, the TBUT was measured using a slit lamp with maximum cobalt blue light. The patients were asked to open the eye widely and look straight ahead. The time before the appearance of defect in the stained tear film was recorded as the TBUT.

Corneal fluorescein staining {#sec2-4}
----------------------------

Corneal integrity was evaluated by fluorescein staining using a slit-lamp cobalt blue filter 1 min after a drop of 2% sterile fluorescein was instilled into the conjunctival sac. The Oxford grading scheme (score, 0--5) was adopted to evaluate the intensity of corneal staining.\[[@ref17]\]

Schirmer I test {#sec2-5}
---------------

One sterile strip was placed in the lateral canthus of the inferior lid margin of both eyes without topical anesthesia. Participants closed their eyes during the test and the length of wetting was measured and recorded after 5 min.

Tear and serum collection {#sec2-6}
-------------------------

Around 50 μl of tear sample was collected as previously reported. Briefly, a microhematocrit tube (NRIS microhematocrit tube, Herlev, Denmark) was introduced into the inferior tear meniscus and tears were collected into the plastic tube using a bulb attached to one end of the tube. This process was duplicated two or three times at 4--6 min intervals. Venous blood samples were collected into Vacuette tubes and centrifuged at 3000 g for 15 min at 4°C. All samples were stored at --80°C until assay and tested within 2 h after thawing, followed by centrifugation. The samples were diluted 10-fold times before the test.

ELISA measurement for cytokines {#sec2-7}
-------------------------------

ELISA kits were used for measuring serum IL-33, Th2 cytokines (IL-4, IL-5), Th1 cytokines (interferon \[IFN\]-gamma), Treg cytokines (IL-10, transforming growth factor-beta \[TGF-β\]), Th17 cytokines (IL-17), (R and D systems, SA) according to the manufacturer\'s protocols. The detection limits of the assays were as follows: IL-33, 1.65 pg/mL, IL-4, 1.56 pg/mL, IL-5, 7.8 pg/mL, IFN-gamma, 12.5 pg/mL, IL-10, 3.9 pg/mL, IL-17, 15 pg/mL, and TGF-β, 15.4 pg/mL.

Statistical analysis {#sec2-8}
--------------------

Statistical analysis was performed using Mann--Whitney or Wilcoxon signed rank test. The pretest Friedman test was performed for multiple comparisons. The Spearman\'s rank correlation test and coefficient of determination were used to analyze the correlation between the expression of biomarkers. *P* \< 0.05 was considered as significant difference.

Results {#sec1-3}
=======

Demographic characteristics of study population and clinical outcome {#sec2-9}
--------------------------------------------------------------------

Thirty healthy volunteers, 30 patients with NSSDE, and 30 patients with SSDE were enrolled in this study. The demographic characteristics of patients were summarized in [Table 1](#T1){ref-type="table"}. Patients from three groups have comparable age. Symptom and fluorescein staining score were significantly higher in SSDE compared with NSSDE and control group (*P* \< 0.05), whereas TBUT and Schirmer I were significantly lower in SSDE compared with NSSDE and control group (*P* \< 0.05).

###### 

Demographics and clinical characteristics of study participants

![](IJO-66-39-g001)

Th1/Th2/Th17/treg cytokines expression in serum and tears {#sec2-10}
---------------------------------------------------------

Tear IL-4 and IL-5 protein expression in SSDE patients increased significantly compared with controls and NSSDE patients \[[Table 2](#T2){ref-type="table"}\] (*P* \< 0.05). However, the serum Th1/Th2/Th17/Treg and tear Th1/Th17/Treg cytokines expression between different groups showed no significant differences (Data not shown).

###### 

Levels of serum and tear cytokines in Sjogren syndrome dry eye patients, non-Sjogren syndrome dry eye patients, and normal participants
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Elevated tear interleukin-33 protein levels in patients and its relationship with Th cytokines and disease severity {#sec2-11}
-------------------------------------------------------------------------------------------------------------------

The tear IL-33 protein expression in SSDE patients increased significantly compared with controls and NSSDE patients \[[Fig. 1](#F1){ref-type="fig"}\]. Correlation analysis showed that the tear IL-33 expression in SSDE and NSSDE patients was positively correlated to Th2 cytokines \[[Fig. 2](#F2){ref-type="fig"}\]. When the coefficient of determination was introduced, the correlation between IL-33 and Th2 cytokines became weaker (IL-4, *R*^2^ = 0.56; IL-5, *R*^2^ = 0.62). Correlation between the serum levels of IL-33 with Th1/17/Treg cytokines was not found. Moreover, the elevated tear levels of IL-33 were positively correlated with symptom and fluorescein staining score but negatively correlated with tear film breakup time and Schirmer I test in both NSSDE and SSDE patients \[[Table 3](#T3){ref-type="table"}\].

![Tear interleukin-33 levels in tears Sjogren Syndrome dry eye patients and non-Sjogren Syndrome dry eye patients. Compared with non-Sjogren Syndrome group, tear interleukin-33 levels in SS group elevated significantly (*P* \< 0.05). Compared with control group, tear interleukin-33 levels in non-Sjogren Syndrome group elevated significantly (*P* \< 0.05)](IJO-66-39-g003){#F1}

![Correlation between interleukin-33 and Th2 cytokine levels in tears and clinical parameters in dry eye patients. Tear interleukin-33 expression in Sjogren\'s syndrome dry eye and non-Sjogren\'s syndrome dry eye patients was positively correlated to interleukin-4 (a) and interleukin-5 (b) respectively (*r* = 0.75, *P* \< 0.01; *r* = 0.79, *P* \< 0.01)](IJO-66-39-g004){#F2}

###### 

Relationship between tear interleukin-33 level and disease severity in dry eye patients
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Discussion {#sec1-4}
==========

Increasing evidence suggests that all forms of DE are characterized by varying ocular surface inflammation.\[[@ref18]\] Previous studies had shown that the activation and infiltration of pathogenic immune cells, primarily CD4+ helper T cells in the conjunctiva and cornea, contribute to the inflammation in DE.\[[@ref19]\] Consistently, elevated levels of inflammatory cytokines (IL-1, IL-6, TNF-alpha, and IL-17) were also found in the tear fluid and corneal and conjunctival epithelium.\[[@ref15][@ref20]\] However, the process and regulation of inflammation in DE was not clear. In this study, our data showed that elevated tear levels of IL-33 were associated with the Th2 cytokines and disease severity of DE, suggesting that IL-33 may have important roles in Th cell balance in the DE.

Our results showed that local Th2 inflammation was enhanced in both SSDE and NSSDE, especially in SSDE, whereas enhancement of system Th2 inflammation was not found in all groups. However, cytokines involved in the Th2 immune response, such as IL-5, were shown to be elevated in the salivary glands and serum in SS patients.\[[@ref21]\] We also found that tear Th2 cytokines in SSDE were elevated compared with NSSDE patients, suggesting that SSDE contributes to more severe local Th2 inflammation. Interestingly, we did not found increased systemic Th2 response in DE compared with controls, which may be due to a small number of sample size or DE is just a local inflammation.

As for Th1/17/Treg inflammation, both local and system responses were not different among the three groups. SS was thought to be a Th1-dominant disease in the past.\[[@ref22]\] In addition, Th-17, characterized by the secretion of inflammatory cytokines IL-17 and IL-23, was also shown to be involved in autoimmunity and inflammation in SS.\[[@ref23]\] Our data suggests that Th1/17/Treg inflammation was not involved in DE inflammatory processes. Inconsistent with our results, Tan *et al*.\[[@ref24]\] and Lee *et al*.\[[@ref25]\]\'s reports demonstrated enhanced Th17 inflammation in SS, whereas Boehm *et al*.\[[@ref26]\]\'s study suggested that Th1 response was dominant in SS. This discrepancy between our and other study regarding Th17 inflammation in DE may be due to different population or test methods.

IL-33 has the capacity to induce Th2 cytokine production from various immune cells, such as Th2 cells, mast cells, basophils, eosinophils, and newly identified innate immune cells, suggesting that IL-33 may be involved in Th2 cytokine-mediated allergic inflammation.\[[@ref24][@ref25][@ref26]\] Indeed, IL-33 has been implicated in asthma, allergic conjunctivitis, and anaphylactic responses.\[[@ref12][@ref27]\] The previous studies had shown that the IL-33/ST2 axis was involved in the pathogenesis of SS and related to disease activity.\[[@ref28][@ref29]\] However, only serum IL-33 were measured in those studies and local IL-33 in tear was not analyzed. Our results showed that both tear IL-33 and Th2 cytokines expression in SSDE patients increased significantly compared with controls and NSSDE patients. Correlation analysis showed that tear IL-33 expression in SSDE and NSSDE was positively correlated to levels of Th2 cytokines, suggesting that tear IL-33 was involved in local Th2 inflammation. However, the correlation was not as strong as done in coefficient of correlation when coefficient of determination was introduced, suggesting that Th2 inflammation was influenced by multiple factors except for IL-33. The uncorrelated tear levels of IL-33 with Th1/17/Treg suggesting that IL-33 may have no direct effect on Th1/17/Treg regulation.

Moreover, the elevated tear levels of IL-33 and Th2 cytokines (IL-4/IL-5) were positively correlated with symptom scores but negatively correlated with tear film breakup time and Schirmer I test in both NSSDE. These results suggested that IL-33 may play important roles in the regulation of Th balance in the DE and thus lead to the progression of disease.

Conclusion {#sec1-5}
==========

In sum, our results suggest that IL-33 may promote Th2 inflammation in the development of DE and contribute to disease severity. However, further studies with large samples and both *in vivo* and *in vitro* studies were needed to clarify the role of IL-33 and its interaction with the ST2 receptor in the pathogenesis of DE.
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